LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Verve Therapeutics Inc

Closed

11.3 0.53

Overview

Share price change

24h

Current

Min

11.24

Max

11.31

Key metrics

By Trading Economics

Income

19M

-31M

Sales

20M

33M

EPS

-0.35

Profit margin

-94.108

Employees

274

EBITDA

19M

-35M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+34.34% upside

Dividends

By Dow Jones

Next Earnings

6 sie 2025

Market Stats

By TradingEconomics

Market Cap

604M

992M

Previous open

10.77

Previous close

11.3

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

Verve Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

17 cze 2025, 11:56 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion

17 cze 2025, 14:02 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly's $1.3 Billion Bid Sends Verve Therapeutics Stock Soaring. What to Know. -- Barrons.com

17 cze 2025, 12:12 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly's $1.3 Billion Bid Sends Verve Therapeutics Stock Soaring 77%. What to Know. -- Barrons.com

17 cze 2025, 11:01 UTC

Acquisitions, Mergers, Takeovers

This Stock Just Jumped 77% After Eli Lilly Made an Agreed $1.3 Billion Bid -- Barrons.com

17 cze 2025, 10:47 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly: Total Potential Consideration of Up to $13.50 Per Shr in Cash Without Interest >LLY

17 cze 2025, 10:47 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly: Considering Also Includes One Non-Tradeable Contingent Value Right Per Shr That Entitles Holder to Receive Up to an Additional $3 Per Shr >LLY

17 cze 2025, 10:46 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly Will Commence Tender Offer to Acquire All Outstanding Shrs of Verve for Purchase Price of $10.50 Per Shr in Cash >LLY

17 cze 2025, 10:45 UTC

Acquisitions, Mergers, Takeovers

Lilly To Acquire Verve Therapeutics To Advance One-time Treatments For People With High Cardiovascular Risk >LLY VERV

17 cze 2025, 09:33 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly Close to $1.3 Billion Bid for Biotech, Says Report. Verve Therapeutics Stock Soars 80%. -- Barrons.com

Peer Comparison

Price change

Verve Therapeutics Inc Forecast

Price Target

By TipRanks

34.34% upside

12 Months Forecast

Average 15.06 USD  34.34%

High 24 USD

Low 11 USD

Based on 10 Wall Street analysts offering 12 month price targets forVerve Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

10 ratings

4

Buy

6

Hold

0

Sell

Technical Score

By Trading Central

4.1501 / 5.16Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Very Strong Bearish Evidence

Long Term

Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Verve Therapeutics Inc

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.